AGIOS PHARMACEUTICALS, INC. Income (Loss) from Continuing Operations, Per Basic Share
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Income (Loss) from Continuing Operations, Per Basic Share of -$6.33 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2024-02-15
- AGIOS PHARMACEUTICALS, INC. income (loss) from continuing operations, per basic share for the quarter ending 2022-09-30 was -$1.49.
- AGIOS PHARMACEUTICALS, INC. income (loss) from continuing operations, per basic share for the quarter ending 2022-06-30 was -$1.68.
- AGIOS PHARMACEUTICALS, INC. income (loss) from continuing operations, per basic share for the quarter ending 2022-03-31 was -$1.74.
- AGIOS PHARMACEUTICALS, INC. income (loss) from continuing operations, per basic share for the quarter ending 2021-12-31 was -$1.81.
- AGIOS PHARMACEUTICALS, INC. income (loss) from continuing operations, per basic share for fiscal 2023 was -$6.33.
- AGIOS PHARMACEUTICALS, INC. income (loss) from continuing operations, per basic share for fiscal 2022 was -$4.23.
- AGIOS PHARMACEUTICALS, INC. income (loss) from continuing operations, per basic share for fiscal 2021 was -$5.90.
- AGIOS PHARMACEUTICALS, INC. income (loss) from continuing operations, per basic share for fiscal 2020 was -$4.77.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 6 month | Income (Loss) from Continuing Operations, Per Basic Share 9 month | Income (Loss) from Continuing Operations, Per Basic Share 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$6.33 10-K · filed 2024-02-15 | |||
| 2022-12-31 | -$4.23 10-K · filed 2024-02-15 | |||
| 2022-09-30 | -$1.49 10-Q · filed 2022-11-03 | -$4.90 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | -$1.68 10-Q · filed 2022-08-04 | -$3.41 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | -$1.74 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | -$1.81 10-K · filed 2022-02-24 | -$5.90 10-K · filed 2024-02-15 | ||
| 2021-09-30 | -$1.48 10-Q · filed 2022-11-03 | -$4.13 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | -$1.36 10-Q · filed 2022-08-04 | -$2.66 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$1.31 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$1.22 10-K · filed 2022-02-24 | -$4.77 10-K · filed 2023-02-23 | ||
| 2020-09-30 | -$1.15 10-K · filed 2022-02-24 | -$3.55 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | -$1.18 10-K · filed 2022-02-24 | -$2.41 10-Q · filed 2021-07-29 | ||
| 2020-03-31 | -$1.23 10-K · filed 2022-02-24 | |||
| 2019-12-31 | -$5.02 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |